Stockscreener 앱 받기
19.76
1.72%
-0.345
전일 마감가:
$20.11
열려 있는:
$20.04
하루 거래량:
185.55K
Relative Volume:
6.92
시가총액:
$837.84M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-1.35%
1개월 성능:
+0.00%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$19.66
$20.88
1주일 범위
$19.50
$20.96
52주 변동 폭
$19.26
$24.90
Sionna Therapeutics Inc Stock (SION) Company Profile
SION을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SION
Sionna Therapeutics Inc
|
19.76 | 837.84M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Sionna Therapeutics Inc 주식(SION)의 최신 뉴스
Atlas Venture Fund Xi L.P Reports 6.5% Stake In Sionna Therapeutics As Of Feb 10 - Marketscreener.com
The Surprising Stock Insiders Can’t Stop Buying: What’s the Hype? - MotoPaddock
Sionna Therapeutics: The Biotech Stock Insiders Are Snapping Up! - Smartphone Magazine
Sionna Therapeutics: The Under-the-Radar Insider Favorite You’ve Been Missing - Anexartiti
Biopharma Gamble: Why Insiders Are Betting Big on Sionna Therapeutics - dsa.si
Why Insiders Are Betting Big on Sionna Therapeutics This Year - Bit Perfect Solutions
The Biopharma Gamble: Why Insiders Are Banking on Sionna Therapeutics - Elblog.pl
Is Sionna Therapeutics (SION) Among Stocks Insiders Are Buying This Year? - Yahoo Finance
Sionna therapeutics sees $20.25 million stock purchase by TPG - MSN
Sionna Therapeutics’ $219.2 Million Upsized IPO - Global Legal Chronicle
Major Stock Acquisition Signals Confidence in Sionna Therapeutics - TipRanks
Sionna Therapeutics updates corporate bylaws post-IPO - Investing.com India
Sionna Therapeutics updates corporate bylaws post-IPO By Investing.com - Investing.com Australia
Major Stakeholders Make Bold Moves on Sionna Therapeutics Stock! - TipRanks
Ra capital management acquires $20.25m in Sionna Therapeutics stock By Investing.com - Investing.com Australia
Ra capital management acquires $20.25m in Sionna Therapeutics stock - Investing.com India
Orbimed advisors buys $9.9 million in Sionna Therapeutics stock - Investing.com
Orbimed advisors buys $9.9 million in Sionna Therapeutics stock By Investing.com - Investing.com South Africa
Sionna Therapeutics director Peter Thompson acquires $9.9m in IPO shares - Investing.com Nigeria
Sionna Therapeutics, Inc. Completes Upsized IPO Raising Approximately $219.2 Million to Advance Cystic Fibrosis Treatments - Nasdaq
Sionna Therapeutics Announces Closing of $219.2 million - GlobeNewswire
Sionna Therapeutics Announces Closing of $219.2 million Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares - Benzinga
Cystic Fibrosis Biotech Startup Secures Massive $219M War Chest in Oversubscribed Nasdaq Debut - StockTitan
Share in cystic fibrosis firm Sionna rise sharply after IPO - pharmaphorum
🔬 Latest pharma industry updates 👇 - substack.com
Vertex Pharma Challenger Sionna Secures $191M in IPO Cash for Cystic Fibrosis Pipeline - MedCity News
Sionna Therapeutics Inc. (SION): RA Capital Backed Biotech IPO Booms in Debut - Smartkarma
Cystic fibrosis drug developer Sionna rises on trading debut - MSN
Strong demand for Sionna latest good sign for IPOs: Public Equity Report - BioCentury
Sionna IPO Grosses $191m To Compete With Vertex In CF - News & Insights
Opening Day: Sionna Therapeutics, Titan America make public debut - TipRanks
Arrowhead appoints Douglas Ingram as new director - MSN
Sionna Therapeutics prices upsized IPO at $18 per share - MSN
Sionna stock rises on trading debut (SION:NASDAQ) - Seeking Alpha
Cystic fibrosis drug developer raises $191M in first Mass. IPO of 2025 - The Business Journals
Sionna goes public in $135M IPO, Aardvark plots $103M listing - Fierce Biotech
Sionna Therapeutics set to open nearly 40% above offer price after upsized $191 mln IPO - TradingView
Sionna Therapeutics Inc. (SION): Biotech Guiding to High-End Pricing; Expecting Strong Outcome - Smartkarma
Goodwin, Ropes Lead Cystic Fibrosis Co.'s Upsized $191M IPO - Law360
ForexTV | Small Business Resources - ForexTV.com
Vertex challenger Sionna prices $191M IPO - BioPharma Dive
Sionna Therapeutics, Inc IPOs Tomorrow, Here's What You Need To Know - Benzinga
Sionna Therapeutics Inc. Prices Upsized Initial Public Offering at $18.00 per Share - Nasdaq
Vera started at buy by Goldman Sachs, atacicept potential cited - MSN
Cystic fibrosis company Sionna seeks $150 million raise in IPO - The Pharma Letter
Major Breakthrough in Cystic Fibrosis Treatment: Sionna Therapeutics Sets Sights on IPO Success - mivalle.net.ar
Waltham biotech plans to raise $150M in IPO this week - The Business Journals
L’Oreal to Sell $3.1 Billion Stake in Sanofi Back to Pharma Group - MSN
Sionna Therapeutics, Inc. (SION): Phase I Cystic Fibrosis Biotech Sets Terms for IPO - Smartkarma
Sionna Therapeutics Set to Make Waves with $150 Million IPO! - Mi Valle
Biotech firm Maze Therapeutics raises $140 million in US IPO - MSN
Sionna Therapeutics Inc (SION) 재무 분석
Sionna Therapeutics Inc (SION)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
Sionna Therapeutics Inc 주식 (SION) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | Director |
Feb 10 '25 |
Buy |
18.00 |
1,125,000 |
20,250,000 |
6,923,365 |
| ORBIMED ADVISORS LLC | Director |
Feb 10 '25 |
Buy |
18.00 |
550,000 |
9,900,000 |
3,704,959 |
| Thompson Peter A. | Director |
Feb 10 '25 |
Buy |
18.00 |
550,000 |
9,900,000 |
3,704,959 |
| Booth Bruce | Director |
Feb 10 '25 |
Buy |
18.00 |
60,000 |
1,080,000 |
807,727 |
| Atlas Venture Fund XI, L.P. | 10% Owner |
Feb 10 '25 |
Buy |
18.00 |
60,000 |
1,080,000 |
807,727 |
0.27%
3.05%
자본화:
|
볼륨(24시간):